[Upcoming Webinar] Breaking the Delivery Barrier: Optimizing LNPs for Precision CRISPR/Cas9 Gene Editing
By Smith Gemini 13-04-2026 1
Lung cancer remains one of the leading causes of cancer-related deaths globally, making it imperative to develop more effective therapies. KRAS mutations are found in a significant percentage of lung cancer cases, presenting a particularly challenging target due to their complex nature. Traditional treatment strategies often fall short, highlighting the urgent need for innovative approaches to precisely target and treat these mutations.
We are excited to invite Dr. Simone Pinto Carneiro to present her pioneering research on using CRISPR/Cas9 gene editing delivered via lipid nanoparticles (LNPs) for lung cancer treatment.
In this webinar, Dr. Carneiro will introduce her team's work on optimizing lipid nanoparticles (LNPs) to enhance the delivery and effectiveness of CRISPR/Cas9 for targeting KRAS mutations in lung tumors. She will guide us through the process of LNP formulation optimization, including formulation screening, physicochemical characterization, and rigorous in vitro and in vivo safety and efficacy assessments.
Key points to be discussed during the session:
How optimizing lipid nanoparticles (LNPs) can significantly improve CRISPR/Cas9 gene editing efficiency and targeting of KRAS mutations
The strategic potential of CRISPR/Cas9-LNPs for precise mutation-specific targeting in lung cancer models
The promise of CRISPR/Cas9-LNPs as inhalable therapeutics, providing a non-invasive, localized approach to treat lung tumors
Why LNP Optimization is the Key
Lipid Nanoparticles (LNPs) have revolutionized the delivery of nucleic acids, as seen in the success of mRNA vaccines. Yet, delivering CRISPR components to lung tumors requires a higher level of sophistication. Factors such as endosomal escape, tissue-specific targeting, and serum stability are all dictated by the precise chemical architecture of the LNP.
Small adjustments in the molar ratios of ionizable lipids, helper lipids, and PEG-lipids can mean the difference between clinical success and therapeutic failure.
What You Will Learn
This webinar dives deep into the engineering strategies used to bypass biological barriers. Key highlights include:
Custom Formulation: How to tailor LNP compositions specifically for large CRISPR/Cas9 mRNA and sgRNA payloads.
Targeting Lung Microenvironments: Innovative chemical modifications that prioritize LNP accumulation in lung tissues.
In Vivo Performance: Real-world data demonstrating enhanced gene editing efficiency in lung tumor models.
Scalability & Stability: Transitioning from benchtop formulations to clinical-grade production.
Join the Discussion
Whether you are a molecular biologist, a formulation scientist, or a drug developer, this session will provide actionable insights into the future of non-viral delivery systems. Stay ahead of the curve and learn how to optimize your delivery platform for maximum impact.
Reserve your spot today by clicking the link below:
Register Now: Optimization of Lipid Nanoparticles for CRISPR/Cas9 Delivery
Webinar at a Glance
Topic: Optimization of Lipid Nanoparticles for CRISPR/Cas9 Delivery
Date: May 19, 2026
Speaker: Leading Scientists from Creative Biolabs
Cost: Free Registration
Meet Our Expert Speaker
We are honored to host Dr. Simone Pinto Carneiro, a distinguished pharmacist and Group Leader at LMU Munich. With over a decade of expertise in RNA-lipid nanoparticle engineering, Dr. Carneiro has been at the forefront of developing non-viral delivery strategies for pulmonary diseases. In this session, she will share her team's pioneering research on optimizing LNPs to specifically target KRAS mutations in lung cancer models, offering a rare look at the data driving the next generation of gene therapies.
Tags : .....
